NEW YORK, March 7, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on BRKR, DXCM, NVTA, and IQV which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market, WallStEquities.com covers four stocks in the Medical Laboratories and Research
Shares in Billerica, Massachusetts headquartered Bruker Corp. climbed 1.75%, ending Tuesday's trading session at $30.17. The stock recorded a trading volume of 327,088 shares. The Company's shares have gained 27.25% over the past year. The stock is trading 2.30% below its 200-day moving average. Moreover, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have a Relative Strength Index (RSI) of 36.13.
On March 01st, 2018, Bruker announced the appointment of Dr. Burkhard Prause, President of the Bruker Energy & Supercon Technologies (BEST) segment, as an executive officer of the Corporation. Dr. Prause has a successful track record of leading BEST through a significant expansion of its business in the last decade, with a focus on customer needs, productivity, quality, and innovation. Get the full research report on BRKR for free by clicking below at: www.wallstequities.com/registration/?symbol=BRKR
San Diego, California headquartered DexCom Inc.'s stock jumped 7.39%, closing the day at $59.84. A total volume of 1.70 million shares was traded, which was above their three months average volume of 1.23 million shares. The Company's shares have advanced 4.47% in the past month and 3.14% in the previous three months. The stock is trading 6.17% above its 50-day moving average. Additionally, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 65.16.
On February 12th, 2018, DexCom announced that Steven Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the Company at the Barclays Global Healthcare Conference on March 13th, 2018, at 2:35 p.m. ET in Miami Beach, Florida. The presentation, which will occur live at the Loews Miami Beach Hotel, will be concurrently webcast on the Company's website. Access the free research report on DXCM now by signing up at: www.wallstequities.com/registration/?symbol=DXCM
On Tuesday, shares in San Francisco, California headquartered Invitae Corp. recorded a trading volume of 744,695 shares. The stock ended the day 3.28% higher at $7.25. The Company's shares have advanced 11.20% in the past month. The stock is trading below its 50-day moving average by 3.08%. Furthermore, shares of Invitae, which focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare in the US, Canada, Israel, and internationally, have an RSI of 55.21.
On February 13th, 2018, research firm The Benchmark Company reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $11 a share to $10 a share.
On February 26th, 2018, Invitae announced that Sean George, CEO, will present at the Cowen and Company 38th Annual Health Care Conference on March 12th, 2018, at 11:20 a.m. ET in Boston, Massachusetts. A live webcast of the presentation may be accessed under the investors section of the Company's website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on NVTA at: www.wallstequities.com/registration/?symbol=NVTA
Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock rose slightly by 0.97%, finishing yesterday's session at $100.66 with a total trading volume of 615,277 shares. The Company's shares have advanced 0.12% in the last month and 29.22% over the past year. The stock is trading above its 50-day and 200-day moving averages by 0.54% and 4.50%, respectively. Additionally, shares of IQVIA, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 53.67.
On February 14th, 2018, IQVIA reported its financial results for the fourth quarter and full year ended December 31st, 2017. For Q4 2017, revenue was $2,161 million, adjusted EBITDA was $582 million, and GAAP net income was $1,076 million. For the full year 2017, revenue was $8,060 million, adjusted EBITDA was $2,047 million, and GAAP net income was $1,309 million. Aspiring Member, please take a moment to register below for your free research report on IQV at: www.wallstequities.com/registration/?symbol=IQV
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-medical-research-stocks----bruker-dexcom-invitae-and-iqvia-300609718.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All